Please login to the form below

Not currently logged in

Paul Blake joins Oxford BioMedica

He will lead the development of pipeline of gene and cell therapies
paul blake oxford biomedica

Oxford BioMedica has named Dr Paul Blake as chief development officer.

Dr Blake, who is already a board member at the UK-based gene therapy specialist, will assume his new role on September 1. He will head the clinical development of the company's pipeline of gene and cell therapies.

Prior to taking the position at Oxford BioMedicia Dr Blake was senior VP and chief medical officer of Canada-based biopharma AEterna Zentaris- a position he held from 2006 to 2014.

His career includes senior managed roles at Cephalon and a senior VP position at SmithKline Beecham Pharmaceuticals, now GSK.

John Dawson, CEO of Oxford BioMedica, said: “His insight and guidance as a Non-Executive Board member have been invaluable and his extensive experience in the strategic clinical development of innovative therapies will be important to Oxford BioMedica as we continue to develop our broad pipeline of novel gene and cell therapies.”

27th August 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...